PAP
REGN icon

Persistent Asset Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Persistent Asset Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-46
Closed -$112K – 226
2025
Q1 		$112K Buy
+46
New +$31.6K 0.09% 115

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Persistent Asset Partners's REGN Position: Q1 2026 in Review

Persistent Asset Partners reduced its Regeneron Pharmaceuticals (REGN) stake by 85% in Q1 2026, selling an estimated $1.78M and leaving 400 shares worth $309K. The position accounts for 0.12% of the portfolio, ranked #153.

Persistent Asset Partners first reported a position in REGN in Q1 2025 and has held it in 5 quarters since. The position peaked at $4.43M in Q1 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Persistent Asset Partners held 400 shares of Regeneron Pharmaceuticals worth $309K as of Q1 2026.
  • Persistent Asset Partners sold 2,331 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $1.78M.
  • Regeneron Pharmaceuticals made up 0.12% of Persistent Asset Partners's portfolio in Q1 2026, its #153 holding.
  • Persistent Asset Partners first reported a position in Regeneron Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • Persistent Asset Partners's Regeneron Pharmaceuticals position peaked at $4.43M in Q1 2025.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.